Hydronidone (F351)

About Gyre Therapeutics

Gyre Therapeutics is a San Diego-based biotech focused on developing treatments for organ fibrosis, with a core mission to address the high unmet need in chronic liver and metabolic diseases. Its key achievement is the advancement of Hydronidone, which has secured Breakthrough Therapy designation in China for Hepatitis B-induced liver fibrosis and is now in a pivotal Phase 3 trial, while a Phase 2b study in MASH is planned for the U.S. The company's strategy is bifurcated: driving its lead candidate in major Western markets while leveraging its controlling interest in Beijing Continent to develop and commercialize a broader portfolio of fibrosis therapies across multiple indications in China and beyond.

About Gyre Therapeutics

Gyre Therapeutics is a San Diego-based biotech focused on developing treatments for organ fibrosis, with a core mission to address the high unmet need in chronic liver and metabolic diseases. Its key achievement is the advancement of Hydronidone, which has secured Breakthrough Therapy designation in China for Hepatitis B-induced liver fibrosis and is now in a pivotal Phase 3 trial, while a Phase 2b study in MASH is planned for the U.S. The company's strategy is bifurcated: driving its lead candidate in major Western markets while leveraging its controlling interest in Beijing Continent to develop and commercialize a broader portfolio of fibrosis therapies across multiple indications in China and beyond.

Therapeutic Areas